Cover Image
市場調查報告書

改變R&D和醫療的提供的穿戴式終端

Wearables are Transforming R&D and Care Delivery

出版商 Datamonitor Healthcare 商品編碼 363584
出版日期 內容資訊 英文 55 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
改變R&D和醫療的提供的穿戴式終端 Wearables are Transforming R&D and Care Delivery
出版日期: 2016年06月06日 內容資訊: 英文 55 Pages
簡介

在醫療IT的演進架構中,醫療領域也開始急速採用穿戴式終端,在經濟性和R&D的實行方面皆取得重要的成果。根據National Institutes of Health的2015年終發表的報告,穿戴式終端關聯的現在進行中的臨床試驗數估計擴展到300件。

本報告提供穿戴式終端對醫療部門的影響調查,穿戴式終端的概要與對醫藥品經營者來說的重要性,穿戴式終端的製造商,醫療部門中穿戴式終端利用的推進因素、阻礙要素,經營者間聯盟的目前配合措施的案例研究,對醫藥品R&D的影響,投資回收可能性高的領域的檢驗等彙整資料。

摘要整理

  • 所謂穿戴式終端對、對醫藥品經營者來說的重要性
  • 穿戴式終端廠商:是醫藥品經營者的合作夥伴嗎?還是對手?
  • 對穿戴式終端的R&D、其他的初期影響
  • 醫療部門的穿戴式終端:推進因素、障礙
  • 各種經營者、設備、治療領域相關的案例研究
  • 穿戴式終端:數位健康投資的一部分

所謂穿戴式終端、對醫藥品經營者來說的重要性

  • 健康和醫療:界線模糊化
  • 患者中心的醫療的實現:成本的削減
  • 參考文獻

穿戴式終端廠商:是醫藥品經營者的合作夥伴嗎?還是對手?

  • 穿戴式終端的製造商
  • 數位健康的革新的強化與資金籌措
  • 參考文獻

穿戴式終端的R&D、對其他的初期影響

  • 到目前為止的大部分實驗是可行性調查
  • 參考文獻

醫療部門的穿戴式終端:推進因素、障礙

  • 推進因素
  • 障礙
  • 參考文獻

穿戴式終端:案例研究

  • 各種價值鏈、相關利益者所使用的穿戴式終端
  • Biogen-Google:多發性硬化症的經過闡明
  • Novartis-Qualcomm:建立行動臨床實驗的基礎
  • Novartis-Microsoft:多發性硬化症的檢測
  • UCB-MC10:帕金森氏症的診斷、治療的改善
  • Johns Hopkins-Apple:利用Apple Watch的發作預測
  • UnitedHealthcare-Qualcomm:階段性支付
  • Medibio-Medtronic:憂鬱症的診斷
  • Google (Verily)-Dexcom:糖尿病患者的粘貼型葡萄糖監測
  • 大塚製藥-Proteus Digital Health:數位醫療改善成果的可能性和法律規章上的對應
  • 參考文獻

穿戴式終端:數位健康投資的一部分

  • 無法定量的投資
  • 提高有效性
  • 醫療的穿戴式終端:支付者是誰
  • 技術性未來性
  • 參考文獻

附錄

目錄
Product Code: DMKC0160959

Wearables encompass the growing range of gadgets that can be attached to the body to measure certain physiological parameters. They are rapidly being adopted in healthcare, as part of a broader health IT revolution, with significant consequences for pharma in both the economics and execution of R&D. There are already an estimated 300 trials underway involving wearables, according to National Institutes of Health data reported in late

2015. Wearables' most immediate potential is in chronic diseases.

This report addresses the following questions:

  • What are wearables and how are they impacting pharma?
  • Who is developing wearables and what partnerships have pharma companies forged as they venture into this new domain?
  • What are the key drivers and resistors to wearables' use in healthcare?
  • How has pharma experimented with wearables so far and what are the key takeaways for drug developers?
  • What impact have wearables had on pharma R&D so far?
  • How will wearables fit within the pharma business model and where is there most potential to generate return on investment from wearables?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • 1. What are wearables, and why should pharma care?
  • 2. Wearables makers: pharma partners or competitors?
  • 3. Wearables' early impact in R&D and beyond
  • 4. Drivers and resistors of wearables in healthcare
  • 5. Case studies involve a range of players, devices, and therapy areas
  • 6. Wearables are part of digital health investments

WHAT ARE WEARABLES, AND WHY SHOULD PHARMA CARE?

  • 7. Wellness and medicine: blurring boundaries
  • 8. Enabling patient centricity; lowering costs
  • 9. Bibliography

WEARABLES MAKERS: PHARMA PARTNERS OR COMPETITORS?

  • 10. Who is making wearables?
  • 11. Fostering and funding digital health innovation
  • 12. Bibliography
  • WEARABLES' EARLY IMPACT IN R&D AND BEYOND
  • 13. Most wearables trials to date have been feasibility studies
  • 14. Bibliography

DRIVERS AND RESISTORS OF WEARABLES IN HEALTHCARE

  • 15. Drivers
  • 16. Resistors
  • 17. Bibliography

WEARABLES CASE STUDIES

  • 18. Wearables are used along the value chain and across stakeholders
  • 19. Biogen-Google: uncovering the course of multiple sclerosis
  • 20. Novartis-Qualcomm: building the foundations for mobile trials
  • 21. Novartis-Microsoft: measuring multiple sclerosis
  • 22. UCB-MC10: improving diagnosis and treatment of Parkinson's disease
  • 23. Johns Hopkins-Apple: using Apple Watch to predict seizures
  • 24. UnitedHealthcare-Qualcomm: paying for steps
  • 25. Medibio-Medtronic: diagnosing depression
  • 26. Google (Verily)-Dexcom: stick-on glucose monitors for diabetes
  • 27. Otsuka-Proteus Digital Health: digital medicines may improve outcomes but first must pass regulatory muster
  • 28. Bibliography

WEARABLES ARE PART OF DIGITAL HEALTH INVESTMENTS

  • 29. Unquantified investments
  • 30. Efficacy gains expected
  • 31. Who will pay for wearables in healthcare?
  • 32. The technological future
  • 33. Bibliography

APPENDIX

  • 34. About the author
  • 35. Scope
  • 36. Methodology
Back to Top